Table of Content

Introduction
Executive Summary
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• CAR T-Cell Therapy for Non-Hodgkin’s lymphoma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Early Stage Products (Phase I/II)
• Comparative Analysis
JCAR017: Juno Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Early Stage Products (Phase I)
• Comparative Analysis
CB010: Caribou Biosciences
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report?..
Inactive Products
• Comparative Analysis
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Key Companies
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Key Products
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma - Unmet Needs
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma - Market Drivers and Barriers
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma - Future Perspectives and Conclusion
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Analyst Views
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Key Companies
Appendix



List of Figures


Figure 1 Total Products for CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


List of Tables


Table 1 Total Products for CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products